Mini-review: pump therapy in endocrinology & metabolism beyond diabetes

Helvacı B. C. , BAŞER H., ÇAKIR B.

Endocrine, 2022 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1007/s12020-022-03007-w
  • Journal Name: Endocrine
  • Journal Indexes: Science Citation Index Expanded, Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: Adrenal insufficiency, Congenital adrenal hyperplasia, Hormone replacement, Hypoparathyroidism, Pump


© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Abstract: The first pump developed by Dr. Kadish and his team in 1963 aimed to “continue subcutaneous insulin infusion”. The number of patients using insulin pumps has increased since the 1980s. This historical perspective has labeled pump therapy in endocrinology and metabolism synonymous with insulin pumps. However, certain other hormonal disorders might also benefit from this kind of treatment. Pump therapy is currently the best approach to achieve physiological mimicry. Furthermore, it may help in overcoming pharmacokinetic issues or allergies. Until now, hormone replacement via pumps has been a salvage method for complex cases at the expense of increased costs. However, it is believed that applications of pump treatment will widen in the future owing to the rapidly evolving technology. In this mini review, data on pump use for patients with adrenal insufficiency, hypogonadism, hypoparathyroidism, congenital adrenal hyperplasia, and congenital hyperinsulinism have been briefly summarized. The study has aimed at covering all the relevant clinical studies and important case reports/series. Methods: A systematic literature search has been conducted on PubMed database seeking articles published until May 2021 using a combination of the following Medical Subject Headings terms and keywords: pump “OR” continue infusion “AND” (adrenal insufficiency “OR” Addison “OR” hydrocortisone “OR” hypoparathyroidism “OR teriparatide” “OR” somatostatin “OR” hypogonadism “OR” hypoglycemia “OR” endocrinology “OR” hormone replacement). In addition, the reference publications in the identified articles have also been reviewed.